Your browser does not support iframes.
This Webpage has the following sections:
Teva’s General Criteria for Specialty Medicines
Drug Modalities of interest
Current Technology And Therapeutic Areas Of Interest
TEVA’S GENERAL CRITERIA FOR SPECIALTY MEDICINES:We evaluate opportunities using the following criteria:
Addresses significant unmet medical need
DRUG MODALITIES OF INTEREST:
CURRENT TECHNOLOGY AND THERAPEUTIC AREAS OF INTEREST INCLUDE: A. Late-stage Opportunities Teva is willing to entertain on- or near- market opportunities that complement our commercial presence across all therapeutic areas and across all our commercial regions. Please feel free to contact us should you have a late-stage opportunityB. Central Nervous System (CNS)
Our respiratory portfolio is both broad and deep, occupying a leading position in this therapeutic area. In 2015 we completed the acquisition of the CareTRx platform (Gecko Health Innovations) in support of building a suite of solutions for our patients and physicians
E. Women’s Health
F. New Therapeutic Entities (NTEs)Teva’s R&D strategy builds on strong internal research and external innovation. Our NTE program is aimed at identifying and developing new specialty medicines that provide genuine advances on existing therapies by formulating, delivering, or using them in a unique way. Currently the NTE program has several R&D products in its pipeline in multiple therapeutic areas. The NTE pipeline features potential breakthrough therapies that will help transform patient care and sustain future growth. To learn more about NTEs please click here >Successful NTE partnering opportunities have the following attributes:
G. BiosimilarsTeva understands the potential biosimilars have as a growth driver to our long term strategy. We currently have 3 marketed biosimilar products Eporatio (epoetin theta), Ovaleap® (follitropin alfa) and Tevagrastim (filgrastim) and will be an active player in biosimilars. Successful biosimilar opportunities would have the following attributes:
H. DiagnosticsTeva is interested in technologies that support our therapeutic areas from diagnosis to disease monitoring,. All development stages of diagnostics are relevant. Primary interest is focused on:
I. Technologies and Patient SolutionsTeva is very interested in cutting edge technologies. We recently announced deals with Microchips and the acquisition of the CareTRx (Gecko Health Innovations) platform
European and Growth Market Opportunities
For the European markets we are looking for products to market and distribute which leverage our existing speciality portfolio and commercial platforms. We are mainly looking for products in pre-registration or at commercial stages – however are also willing to assist a partner to get a late-stage drug approved in Europe and to help build a value-proposition for its pricing, reimbursement and market access. We prefer a region-wide deal, but are also well skilled and familiar with country-by-country distribution, co-marketing or co-promotion arrangements.We offer broad commercial coverage, excellent relationships with regulators and pricing agencies, and can communicate the value proposition of what the product brings to the patients.Growth Markets:
The Teva Growth Markets region includes all ex US/EU countries. Teva has a leading position, established presence and strong sales, marketing & regulatory capabilities, in key growth markets including Japan, Russia (+CIS), Turkey, Israel, Australia (+NZ) South Korea, and LATAM (Brazil, Mexico, Argentina, Chile, Peru and Venezuela).For these markets and others we are looking for new products to market and distribute, to leverage on our strong regulatory and commercial platforms. We are looking for commercial products, as well as products in advanced development (Phase III and pre-registration stages)Teva can offer dedicated, experienced, multinational & local leading partnerships in multiple territories.
Over the Counter
OTC’sSince 2011, Teva's OTC business has been integrated with the OTC business of the Procter & Gamble Company, under our global (excluding N. America) joint venture - PGT Healthcare. PGT Healthcare consolidates, manages and is focused on growing all Teva and P&G OTC and Vitamins, Minerals and Supplements (VMS) businesses, outside of North America.PGT Healthcare’s portfolio includes Vicks — the world’s #1 selling cough & cold brand, Ratiopharm — the #1 OTC brand in Germany, and other leading brands like Vibovit, Ambrobene, Hylak, Novo-Passit, and Gastal.We have more than 160 brands, sold in more than 65 countries
We offer:Exceptional partnering opportunities, with a portfolio of leading brands, supported by best-in-class consumer understanding, brand-building and advertising scale, as well as global capabilities in product development, registration and manufacturing.
We also offer go-to-market scale across all retail channels, with a wide geographical footprint.We are interested in:Worldwide opportunities in licensing-in of developments and transfer of available registration dossiers (EU CTD and other registrable formats) for Over the Counter(OTC), Food Supplements and Medical Devices categories.Preference is given to the therapy areas of Cough & Cold, VMS (Vitamins, Minerals and Supplement), Digestive Health, Probiotics, Gastroenterology, and Pain Management.Early launch opportunities in emerging markets, especially LATAM and AsiaNew and novel technologies, delivery platforms, product presentations, dosage forms and packaging ideas.
Teva wants to hear from you!Our business development activities are led by pharmaceutical professionals with extensive experience in managing discussions, structuring deals and executing agreements.Please feel free to send us your opportunities through the email below. We make it our business to provide timely feedback.